FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER

• 1. 用于治疗尿路上皮癌的FGFR酪氨酸激酶抑制剂 [P] . 中国专利： CN113645975A . 2021-11-12
• 2. 用于治疗尿路上皮癌的FGFR酪氨酸激酶抑制剂 [P] . 中国专利： CN113645974A . 2021-11-12
• 3. PACLITAXEL-HYALURONIC ACID CONJUGATE IN THE TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER [P] . US2021196833A1 . 2021-07-01

  机译： 紫杉醇 - 透明质酸缀合物治疗非肌肉侵袭性膀胱癌

• 4. Paclitaxel-Hyaluronic Acid Conjugate in the Treatment of Non-Muscle Invasive Bladder Cancer [P] . KR20210083249A . 2021-07-06

  机译： 紫杉醇 - 透明质酸缀合物治疗非肌肉侵袭性膀胱癌

• 5. Azolium salts for treatment of non-muscle invasive bladder cancer [P] . US11197873B2 . 2021-12-14

  机译： 氮杂盐治疗非肌肉侵袭性膀胱癌

• 1. The efficacy of Kanglaite injection during treatment with tyrosine kinase inhibitor in elderly patients with non-small cell lung cancer [J] . Wei Zhou, Tao Han, Zhaozhe Liu, 肿瘤学与转化医学（英文） . 2017,第003期
• 2. Efficacy of pemetrexed combined with erlotinib/gefitinib in advanced non-small cell lung cancer patients during tyrosine kinase inhibitor treatment [J] . Guanzhong Zhang, Zhaozhe Liu, Tao Han, 肿瘤学与转化医学（英文） . 2017,第003期
• 3. Efficacy of pemetrexed combined with erlotinib/gefitinib in advanced non-small cell lung cancer patients during tyrosine kinase inhibitor treatment [J] . Guanzhong Zhang, Zhaozhe Liu, Tao Han, 中德临床肿瘤学杂志（英文版） . 2017,第003期
• 4. Improved temperature monitoring and treatment planning for loco-regional hyperthermia treatments of Non-Muscle Invasive Bladder Cancer (NMIBC) [C] . G. Schooneveldt, H.P. Kok, E.D. Geijsen World Congress on Medical Physics and Biomedical Engineering . 2015
• 5. Understanding treatment-related symptoms, symptom management techniques, and symptom management self-efficacy in a sample of non-muscle invasive bladder cancer patients [D] . Hinojosa-Lindsey, Marilyn 2010
• 6. Should intravesical Bacillus Calmette–Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer? [O] . Hyeong Dong Yuk, Chang Wook Jeong, Cheol Kwak, -1
• 7. Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer [O] . Sahyun Pak, Sun-Young Kim, Sung Han Kim, 2021
• 8. Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Technology Assessment Report [R] . Terasawa, T., Dahabreh, I., Castaldi, P. J., 2010

• 1. Recirculating chemohyperthermia as a treatment for non-muscle invasive bladder cancer:Current and future perspectives [J] . Javier Flores-Carbajal1 ,Alejandro Sousa-Escandón1 ,Daniel Sousa-Gonzalez1 . 世界临床泌尿杂志 . 2017,第002期
• 2. Association between Subjective Evaluation of Skin Toxicities and Quality of Life in Patients with Lung Cancer Undergoing Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Pilot Study for Developing Skin Toxicity Assessment [J] . Kengo Hirayama ,Ya Su ,Yasuyuki Ikezawa . 护理学期刊（英文） . 2019,第12期
• 3. 酪氨酸激酶抑制剂基础上异基因造血干细胞移植优于酪氨酸激酶抑制剂单药治疗慢性髓性白血病急变期患者 [C] . 江浩 ,许兰平 ,刘代红 . 中华医学会第十二次全国血液学学术会议 . 2012
• 4. 基于FGF/FGFR靶点的8--取代鸟嘌呤类酪氨酸激酶小分子抑制剂的设计、合成及其抗肿瘤活性的探讨 [A] . 肖彤 . 2012